Alterations of choline phospholipid metabolism in ovarian tumor progression

Cancer Research

Volumn 65, Issue 20, 2005, Pages 9369-9376

  Iorio, Egidio ^a   Mezzanzanica, Delia ^b   Alberti, Paola ^b   Spadaro, Francesca ^a   Ramoni, Carlo ^a   D'Ascenzo, Sandra ^c   Millimaggi, Danilo ^c   Pavan, Antonio ^c   Dolo, Vincenza ^c   Canevari, Silvana ^b   Podo, Franca ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; CHOLINE; CHOLINE KINASE; GLYCEROPHOSPHORYLCHOLINE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPASE C; PHOSPHOLIPASE D; PHOSPHORYLCHOLINE;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOMA CELL; CATABOLISM; CELL IMMORTALIZATION; CULTURE MEDIUM; DIAGNOSTIC VALUE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; OVARY CARCINOMA; PHOSPHOLIPID METABOLISM; PHOSPHOLIPID SYNTHESIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ASSAY;

CARBON RADIOISOTOPES; CELL LINE, TUMOR; CHOLINE; CHOLINE KINASE; DISEASE PROGRESSION; FEMALE; HUMANS; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; OVARIAN NEOPLASMS; PHOSPHATIDYLCHOLINES; PHOSPHOLIPASE C; PHOSPHOLIPASE D; PHOSPHORYLCHOLINE;

EID: 27144444683     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1146     Document Type: Article

References (50)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Ozols RF, Bookman MA, Connolly DC, et al. Focus on epithelial ovarian cancer. Cancer Cell 2004;5:19-24.
3. Balli S, Fey MF, Hanggi W, et al. Ovarian cancer. An institutional review of patterns of care, health insurance and prognosis. Eur J Cancer 2000;36:2061-8.
4. Negendank WG. Studies of human tumors by MRS: a review. NMR Biomed 1992;5:303-24.
5. 31P MRS of experimental tumours. NMH Biomed 1993;6:345-65.
6. Podo F. Tumour phospholipid metabolism. Review article. NMR Biomed 1999;12:413-39.
7. Ackerstaff E, Glunde K, Bhujwalla ZW. Choline phospholipid metabolism: a target in cancer cells? J Cell Biochem 2003;90:525-33.
8. Kurhanewicz J, Vigneron DB, Nelson SJ. Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. Neoplasia 2000;2:166-89.
9. Katz-Brull R, Lavin PT, Lenkinski RE. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J Natl Cancer Inst 2002;94:1197-203.
10. 18F-Fluorocholine: a new oncologic PET tracer. J Nucl Med 2001;42:1815-7.
11. 18F-FDG PET. J Nucl Med 2003;44:1051-6.
12. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999;9:80-4.
13. Glunde K, Jie C, Bhujwalla M. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res 2004;64:4270-6.
14. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 2001;61:3599-603.
15. Okada T, Harada M, Matsuzaki K, Nishitani H, Aono T. Evaluation of female intrapelvic tumors by clinical proton MR spectroscopy. J Magn Reson Imaging 2001;13:512-7.
16. 1H MR spectra of biopsies from untreated and recurrent ovarian cancer using linear discriminant analysis. Magn Reson Med 1997;38:569-76.
17. 1H NMR study. Br J Cancer 2002;86:1180-7.
18. Kruk PA, Maines-Bandiera SL, Auersperg NA. Simplified method to culture human ovarian surface epithelium. Lab Invest 1990;63:132-6.
19. Benard J, Da Silva J, De Blois MC, et al. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res 1985;45:4970-9.
20. Hamilton TC, Young RC, McKoy WM, et al. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res 1983;43:5379-89.
21. Fogh J, Fogh JM, Orfeo T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 1977;59:221-6.
22. Bast RC, Jr., Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331-7.
23. Dolo V, Ginestra A, Violini S, et al. Ultrastructural and phenotypic characterization of CABA I, a new human ovarian cancer cell line. Oncol Res 1997;9:129-38.
24. 31P-NMR study. Biochim Biophys Acta 2000;1483:334-42.
25. Podo F, Ferretti A, Knijn A, et al. Detection of phosphatidylcholine- specific phospholipase C in NIH-3T3 fibroblasts and their H-ras transformants: NMR and immunochemical studies. Anticancer Res 1996;16:1399-412.
26. 31P-nuclear magnetic resonance analysis of interferon-induced alterations of phospholipid metabolites in interferon-sensitive and interferon-resistant Friend leukemia cell tumors in mice. Cancer Res 1986;46:2849-57.
27. Podo F, Carpinelli G, Di Vito M, et al. Nuclear magnetic resonance analysis of tumour necrosis factor-induced alterations of phospholipid metabolites and pH in Friend leukemia cell tumors and fibrosarcomas in mice. Cancer Res 1987;47:6481-9.
28. Ishidate K. Choline transport and choline kinase. In: Vance DE, editor. Phosphatidylcholine metabolism. Boca Raton: CRC Press: 1989. p. 9-32.
29. Ramoni C, Spadaro F, Barletta B, Dupuis ML, Podo F. Phosphatidylcholine- specific phospholipase C in mitogen-stimulated fibroblasts. Exp Cell Res 2004;299:370-82.
30. Vance DE, Trip EM, Paddon HB. Poliovirus increases phosphatidylcholine biosynthesis in HeLa cells by stimulation of the rate-limiting reaction catalyzed by CTP: phosphocholine cytidylyltransferase. J Biol Chem 1980;255:1064-9.
31. Warden CH, Friedkin M. Regulation of phosphatidylcholine biosynthesis by mitogenic growth factors. Biochim Biophys Acta 1984;792:270-80.
32. Yoshimoto M, Waki A, Obata A, Furukawa T, Yonekura Y, Fujibayashi Y. Radiolabeled choline as a proliferation marker: comparison with radiolabeled acetate. Nucl Med Biol 2004;31:859-65.
33. Mufson RA, Okin E, Weinstein IB. Phorbol esters stimulate the rapid release of choline from prelabelled cells. Carcinogenesis 1981;2:1095-102.
34. 31P NMR spectra of malignant human mammary epithelial cells during treatment with the anti-inflammatory agent indomethacin. Magn Reson Med 2002;48:819-25.
35. Kaye S, Gershensen D, Hung M, Seiden M. Discussion: molecular therapeutics and pharmacogenomics. Gynecol Oncol 2003;88:S93-6.
36. Steinmetz R, Wagoner HA, Zeng R et al. Mechanisms regulating the constitutive activation of the extracellular signal-regulated kinase (ERK) signaling pathway in ovarian cancer and the effect of ribonucleic acid interference for ERK1/2 on cancer cell proliferation. Mol Endocrinol 2004:182570-82.
37. McDaid HM, Cairns MT, Atkinson RJ, et al. Increased expression of the RIα subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer. Br J Cancer 1999;5-6:933-9.
38. Fang X, Schummer M, Mao M, et al. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta 2002;1582:257-64.
39. Ramirez de Molina A, Rodriguez-Gonzalez A, Lacal JC. From Ras signalling to ChoK inhibitors: a further advance in anticancer drug design. Cancer Lett 2004;206:137-48.
40. Aoyama C, Liao H, Ishidate K. Structure and function of choline kinase isoforms in mammalian cells. Prog Lipid Res 2004;43:266-81.
41. Wieprecht M, Wieder T, Geilen CC. N-[2-bromocinnamyl (amino)ethyl]-5- isoquinolinesulphonamide (H-89) inhibits incorporation of choline into phosphatidylcholine via inhibition of choline kinase and has no effect on the phosphoryiation of CTP:phosphocholine cytidylyltransferase. Biochem J 1994;297:241-7.
42. Bjørkøy G, Overvatn A, Diaz-Meco MT, Moscat J, Johansen T. Evidence for a bifurcation of the mitogenic signaling pathway activated by Ras and phosphatidylcholine-hydrolyzing phospholipase C. J Biol Chem 1995;270:21299-306.
43. Luquain C, Singh A, Wang L, Natarajan V, Morris AJ. Role of phospholipase D in agonist-stimulated lysophosphatidic acid synthesis by ovarian cancer cells. J Lipid Res 2003;44:1963-75.
44. Eder AM, Sasagawa T, Mao M, Aoki J, Mills GB. Constitutive and lysophosphatldic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clin Cancer Res 2000;6:2482-91.
45. Cook GJR. Oncological molecular imaging: nuclear medicine techniques. Br J Radiol 2003;76:S152-8.
46. Tian M, Zhang H, Higuchi T, Oriuchi N, Endo K. Oncological diagnosis using (11)C-choline-positron emission tomography in comparison with 2-deoxy-2-[(18)F] Duoro-D-glucose-positron emission tomography. Mol Imaging Biol 2004;6:172-9.
47. Katz-Brull R, Degani H. Kinetics of choline transport and phosphoryiation in human breast cancer cells: NMR application of the zero trans method. Anticancer Res 1996;16:1375-80.
48. Vance JE, Vance DE. Phospholipid biosynthesis in mammalian cells. Biochem Cell Biol 2004;82:113-28.
49. 18F]dOC). Nucl Med Biol 2004;31:851-8.
50. Yeung DKW, Humairah SC, Gary MKT. Human breast lesions: characterization with contrast-enhanced in vivo proton MR spectroscopyinitial results. Radiology 2001;220:40-6.